Craft

ImpediMed

Stock Price

$0.1

2024-10-04

Market Capitalization

$119.4 M

2024-10-04

Revenue

$12.7 M

FY, 2025

ImpediMed Summary

Company Summary

Overview
ImpediMed is engaged in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. The Company's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor.
Type
Public
Status
Active
Founded
1999
HQ
Pinkenba, AU | view all locations
Website
https://www.impedimed.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Parmjot Bains

    Parmjot Bains, Managing Director & Interim CEO

  • Tim Benkovic

    Tim Benkovic, SVP of Sales & Customer Success

  • Julie Kuhlken

    Julie Kuhlken, Senior Director, Downstream Marketing

  • Dennis Schlaht

    Dennis Schlaht, SVP of R&D and Technology

LocationsView all

2 locations detected

  • Pinkenba, Queensland HQ

    Australia

    Unit 1 50 Parker Ct

  • Carlsbad, CA

    United States

    5900 Pasteur Ct #125

ImpediMed Financials

Summary Financials

Revenue (H1, 2026)
$7.5M
Gross profit (H1, 2026)
$7.3M
Net income (H1, 2026)
($12.3M)
Cash (H1, 2026)
$18.8M
EBIT (H1, 2026)
($10.9M)
Enterprise value
$121.4M

Footer menu